All News

syringe

IV Secukinumab for AxSpa

d Eric Dein, MD

The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. Data for this new approval will be presented at ACR Convergence on November 14th by Dr. Atul Deodhar.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

SGLT2 inhibitors: The new hype in SLE and LN management?

d Sheila Reyes, MD

Inhibitors of SGLT2 have been shown to reduce MACE in patients with type 2 DM and established cardiovascular disease. In patients with chronic kidney disease at risk of progression, SGLT2 inhibitors have shown reduction in risk of eGFR decline and hospitalization. In SLE, clinical trials have yet to explore the possible role of SGLT2i in improving renal outcomes in lupus nephritis. A couple of abstracts presented during the meeting tackled the topic of SGLT2 inhibition in SLE. 

Read Article
Stills,continuum

New Biomarkers and Therapeutics Show Potential in Still's Disease

d Bella Mehta, MBBS, MS

Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis (sJIA) characterized by sustained fever, salmon-colored rash, and arthritis.

Read Article
Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/jjcnekqVPe
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

Early experience w/SGLT2i in SLE (Prof Petri): 👉Reduction of decline in eGFR after SGLT2i 👉Improvement in RUPCR after SGLT2i BUT observed differences not significant when compared w/prior to starting SGLT2i Small sample size. Longer ffup needed. #ACR23 ABST1490 @RheumNow https://t.co/IhVFacRi0g
sheila  ( View Tweet)
Went into more depth on this great topic of IBD in SpA on @RheumNow #ACR23 Should we be screening SpA patients with fecal calprotectin to look for undiagnosed SpA? https://t.co/TmXhm2MEfO https://t.co/SWJSqF5pkW

Eric Dein  ( View Tweet)

You said that CAR-T needs a #RCT in severe #SLE ⁦@RheumNow⁩ ⁦@ACRheum⁩ #ACR23 https://t.co/yilohqz1YE
Janet Pope  ( View Tweet)
Age does NOT affect the chance of getting irAE or the severity when using check point inhibitors to treat cancer. Data from #CANRIO database in #Canada #ACR 23 @ACRheum @RheumNow #1063 https://t.co/bqbiXzdAqr
Janet Pope  ( View Tweet)
#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta
Janet Pope  ( View Tweet)
#ACR23 highlights from PlenaryII 🙉#RA #ILD seems that #TNFi is equal to other bDMARDs - was thought to worsen /cause it. 🙉Septra should be given with #rituximab and #steroids in #GCA to prevent #infections not just #PJP #ACR23 @RheumNow @ACRheum #ACRbest

Janet Pope  ( View Tweet)

@lastwalsh @KyleWalkerM @RheumNow Second question: do you ever give a PEXIVAS-standard style steroid taper? I'm 100% in agreement that we should favor PEXIVAS over observational data in most cases In practice it seems like some patients need a bit more immunosuppression, though Curious to hear your thoughts!

Mike Putman EBRheum ( View Tweet)

#Infection rates are equal in #RWD #real #world #data using #biosimilars compared to previous use of #originators. BC database #0970 #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ #arthritisresearchcanada #ARC https://t.co/eVSPgVfmQG
Janet Pope  ( View Tweet)
#ACR23 Abs #2199 large RL study: SEC retention rates after 4 yrs approx. 50% in axSpA and PsA pts. Bio-naïve pts had higher retention, remission & response rates than pts with prior b/tsDMARD exposure, particularly in axSpA. https://t.co/Eq5BwILK3D @rheumnow https://t.co/slho6yAwtQ
Dr. Rachel Tate  ( View Tweet)
SPARTAN referral recommendations for axSpA #ACR23 Abs #2214 https://t.co/VQedpNynpv support Abs #2207 https://t.co/8RB0D4ef7i findings discussing that non-rheums are less aware of IBP components/asking about them in CBP pts. @rheumnow https://t.co/23oUONsMfb
Dr. Rachel Tate  ( View Tweet)
The presence of antibodies to 4 UH-axSpA peptides was confirmed in the Belgian Inflammatory Arthritis and Spondylitis (Be-Giant) cohort of newly diagnosed axSpA patients and could be of added value for axSpA diagnosis. #ACR23 Abs #2210 https://t.co/fV4PPbWF01 @rheumnow

Dr. Rachel Tate  ( View Tweet)

1-PJP prophylaxis or not in ANCA? 2-MTX single dose or split dose? 3-IL6 blocker early on in GCA/PMR? 4-SGLT2 in DM/Lupus nephritis? 5-Cervical cancer screening in Lupus? 6-TNF induced ILD? https://t.co/mzGXajmQqE @RheumNow , Daily recap #ACR23

Nouf Al hemmadi  ( View Tweet)

PtGA and PhGA were aligned in most encounters in PsA. PtGA >PhGA disagreement was driven by pain, fatigue, and physical health being weighed more by Pts than Phs. PROs matter! #ACR23 Abs #2234 https://t.co/0r7gjx0JS6 @rheumnow https://t.co/BuGDicwBiB
Dr. Rachel Tate  ( View Tweet)
Watch: Lupus and the Patient Perspective Dr. Kathryn Dao talks with patient advocate Amanda Greene about her patient poster (PP03) on "Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime" at #ACR23. https://t.co/JKU3w7sz4j https://t.co/IWHLJEi0qG

Links:

Dr. John Cush RheumNow ( View Tweet)
C9n @RheumNow, excelente persona. Gracias!! https://t.co/pGZnMHApQH
José Navia Dongo  ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×